)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Cadrenal Therapeutics
Cadrenal Therapeutics (CVKD) investor relations material
Cadrenal Therapeutics 2nd Annual Lytham Partners Healthcare Investor Summit summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.2nd Annual Lytham Partners Healthcare Investor Summit summary15 Jan, 2026
Strategic positioning and program overview
Focuses on bridging gaps in anticoagulation for rare and high-risk patients, especially where current DOACs and warfarin are inadequate.
Lead program Tecarfarin targets end-stage renal disease with atrial fibrillation and patients with implanted devices, holding orphan drug designations.
VLX-1005, recently acquired, targets heparin-induced thrombocytopenia (HIT) and has completed phase 2; Fruinexian, a short-acting Factor XI inhibitor, is in phase 2 for cardiovascular surgery.
Addresses market needs where reversibility and safety are concerns, especially after the withdrawal of Andexxa, a key reversal agent.
Programs are positioned to serve patients who cannot use DOACs and require alternatives to long-standing therapies.
VLX-1005 and 12-LOX inhibition
VLX-1005 is a first-in-class 12-LOX inhibitor, developed to intervene upstream in immune-mediated platelet activation, offering a novel approach to HIT.
Chosen for HIT due to a clear mechanistic tie-in and high unmet need, with current treatments carrying significant bleeding risks.
HIT is a rare but serious complication of heparin therapy, leading to high morbidity and mortality; VLX-1005 aims to reduce bleeding risk by targeting disease pathogenesis.
Orphan Drug and Fast Track designations accelerate development, reduce costs, and provide regulatory advantages.
Broader applicability of 12-LOX inhibition is being explored in other immune-mediated and thrombo-inflammatory diseases, including type 1 diabetes.
Long-term strategy and market opportunity
Portfolio now spans acute immune-mediated platelet activation and acute care coagulation, aiming to replace outdated therapies for underserved populations.
Tecarfarin offers a kidney-friendly alternative for patients with mechanical heart valves or advanced renal disease who cannot use DOACs.
VLX-1005 and Tecarfarin both have Orphan and Fast Track designations, supporting rapid advancement.
Combined peak annual revenue opportunity across targeted indications is estimated at $3 billion.
VLX-1005 is expected to be the primary value driver in the next 3–5 years, followed by Tecarfarin and Fruinexian.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Cadrenal Therapeutics earnings date
Q4 202512 Mar, 2026
Cadrenal Therapeutics
Next Cadrenal Therapeutics earnings date
Q4 202512 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on the development of tecarfarin, an advanced oral anticoagulant. Tecarfarin is designed to prevent heart attacks, strokes, and deaths caused by blood clots, particularly in patients with rare cardiovascular conditions that require long-term anticoagulation therapy. These conditions include end-stage kidney disease (ESKD), atrial fibrillation, and complications related to left ventricular assist devices (LVADs). The company aims to address the limitations of existing anticoagulants like warfarin, offering a more stable and reliable treatment option through an alternative metabolic pathway. The company is headquartered in Ponte Vedra, Florida, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage